South Carolina Patent of the Month – January 2022
Diabetes is a serious disease which impacts every facet of your life. While you cannot cure it, there are medications and practices that can be used to manage it. According to recent data from the American Diabetes Association, there are more than 29 million Americans diagnosed with diabetes. An additional 86 million have been diagnosed with pre-diabetes. Without effective intervention, 15-20% of these pre-diabetic patients will develop diabetes within five years.
Glytec, a subsidiary of Aseko, Inc., has developed innovative insulin management solutions since 2006. Recently, they have developed a software solution which could act as a diabetes management therapy advisor. Patients with diabetes are often prescribed multiple different medications to aid in blood glucose control, hypertension, and dyslipidemia. Tracking the right medication, dosage, and timing can become complex for an individual.
The advisor uses a clinical decision support system to analyze the patient condition parameters and calculate the personalized dose of insulin to bring their blood glucose levels into target range, or to maintain levels within this range. A doctor can provide a generalized dose that should work for the patient in most situations but the required dose may vary over time. If a patient has a sudden spike or drop in blood glucose levels, the generalized dose may not be sufficient.
The system takes into account relevant data such as current patient-state and historical blood glucose data. It also references a domain knowledge base filled with information about diabetes. Based on this information, the system reports the recommended adjusted or prescribed dose to prevent hypoglycemia or hyperglycemia.
These treatment determining algorithms can be coupled with the company’s FDA-cleared titration software to deliver personalized insulin treatment and improving patient care.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
